Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 4, 2011, Pages 1747-1753

  Brown, Ashley N ^a   Bulitta, Jürgen B ^a   McSharry, James J ^a   Weng, Qingmei ^a   Adams, Jonathan R ^a   Kulawy, Robert ^a   Drusano, George L ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZANAMIVIR;

ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; IC 50; INFLUENZA VIRUS A H1N1; MATHEMATICAL MODEL; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; VIROGENESIS; VIRUS INHIBITION; VIRUS LOAD; VIRUS RELEASE; VIRUS REPLICATION;

ANIMALS; AREA UNDER CURVE; CELL LINE; DOGS; MODELS, THEORETICAL; ORTHOMYXOVIRIDAE; ZANAMIVIR;

EID: 79953196507     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01629-10     Document Type: Article

References (28)

1. Baccam, P., C. Beauchemin, C. A. Macken, F. G. Hayden, and A. S. Perelson. 2006. Kinetics of influenza A virus infection in humans. J. Virol. 80:7590-7599.
2. Beal, S. L. 2001. Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinet. Pharmacodyn. 28:481-504.
3. Beauchemin, C. A., et al. 2008. Modeling amantadine treatment of influenza A virus in vitro. J. Theor. Biol. 254:439-451.
4. Brendel, K., E. Comets, C. Laffont, C. Laveille, and F. Mentre. 2006. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm. Res. 23:2036-2049.
5. Brown, A. N., et al. 2011. Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system. Antimicrob. Agents Chemother. 55:1740-1746.
6. Brown, A. N., et al. 2010. In vitro system for modeling influenza A virus resistance under drug pressure. Antimicrob. Agents Chemother. 54:3442-3450.
7. Cass, L. M., C. Efthymiopoulos, and A. Bye. 1999. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin. Pharmacokinet. 36(Suppl. 1):1-11.
8. Cass, L. M., C. Efthymiopoulos, J. Marsh, and A. Bye. 1999. Effect of renal impairment on the pharmacokinetics of intravenous zanamivir. Clin. Pharmacokinet. 36(Suppl. 1):13-19.
9. CDC. 2009. FluView: 2008-2009 influenza season week 38 ending September 26, 2009. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/flu/weekly/.
10. CDC. 2009. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis-North Carolina, 2009. MMWR Morb. Mortal. Wkly. Rep. 58:969-972.
11. CDC. 2009. Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients-Seattle, Washington, 2009. MMWR Morb. Mortal. Wkly. Rep. 58:893-896.
12. CDC. 2009. Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb. Mortal. Wkly. Rep. 58:433-435.
13. CDC. 2010. Patients hospitalized with 2009 pandemic influenza A (H1N1)-New York City, May 2009. MMWR Morb. Mortal. Wkly. Rep. 58:1436-1440.
14. Dawood, F. S., et al. 2009. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 360:2605-2615.
15. Doucette, K. E., and F. Y. Aoki. 2001. Oseltamivir: a clinical and pharmacological perspective. Expert Opin. Pharmacother. 2:1671-1683.
16. Drusano, G. L., et al. 2001. Pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for once-daily dosing. Antimicrob. Agents Chemother. 45:2115-2118.
17. Garten, R. J., et al. 2009. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325:197-201.
18. Gubareva, L. V., R. G. Webster, and F. G. Hayden. 2002. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res. 53:47-61.
19. Hayden, F. G., K. M. Cote, and R. G. Douglas, Jr. 1980. Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob. Agents Chemother. 17:865-870.
20. Itoh, Y., et al. 2009. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460:1021-1025.
21. Jain, S., et al. 2009. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N. Engl. J. Med. 361:1935-1944.
22. McSharry, J. J., Q. Weng, A. N. Brown, R. Kulawy, and G. L. Drusano. 2009. Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. Antimicrob. Agents Chemother. 53:2375-2381.
23. Metzgar, D., et al. 2010. Initial identification and characterization of an emerging zoonotic influenza virus prior to pandemic spread. J. Clin. Microbiol. 48:4228-4234.
24. Moscona, A. 2005. Oseltamivir resistance - disabling our influenza defenses. N. Engl. J. Med. 353:2633-2636.
25. Nguyen, J. T., et al. 2010. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 5:e9332.
26. Nguyen, J. T., et al. 2009. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob. Agents Chemother. 53:4115-4126.
27. Sidwell, R. W., and D. F. Smee. 2002. Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza. Expert Opin. Investig. Drugs 11:859-869.
28. Smee, D. F., B. L. Hurst, M. H. Wong, K. W. Bailey, and J. D. Morrey. 2009. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob. Agents Chemother. 53:2120-2128.